10-Q: LifeMD Narrows Losses, Divests WorkSimpli for Telehealth Focus

LifeMD, Inc. reported a significant reduction in net losses for Q3 and the first nine months of 2025, driven by strong telehealth revenue growth, while announcing the strategic sale of its WorkSimpli subsidiary.

Summary

• Total revenues for the three months ended September 30, 2025, increased by 13% to approximately $60.2 million, up from $53.3 million in the prior year period.
• Total revenues for the nine months ended September 30, 2025, increased by 25% to approximately $187.0 million, up from $149.3 million in the prior year period.
• Telehealth revenue, net, grew by 34% for the nine months ended September 30, 2025, primarily due to increased demand for LifeMD primary care, including its GLP-1 Weight Management Program.
• Net loss attributable to LifeMD, Inc. common stockholders decreased to $(4.6) million for the three months ended September 30, 2025, from $(5.4) million in the prior year period.
• Net loss attributable to LifeMD, Inc. common stockholders decreased to $(7.9) million for the nine months ended September 30, 2025, from $(18.8) million in the prior year period.
• The company repaid the remaining $14.0 million outstanding principal on the Avenue Facility on August 5, 2025, incurring a $1.2 million loss on debt extinguishment.
• LifeMD sold its majority ownership interest in WorkSimpli to Lion Buyer, LLC on November 4, 2025, for an aggregate purchase consideration of up to $52.0 million, with $22.0 million received at closing.
• An additional material weakness in internal control over financial reporting was identified related to the recording of net revenue as an agent in certain third-party pharmacy arrangements.
• The company acquired certain intangible assets of OHHMD, PLLC, a virtual care provider focused on women's health and hormone replacement therapies, on April 24, 2025.
• LifeMD expanded acceptance of insurance to Medicare beneficiaries for qualifying care in April 2025, initially available in 26 states with plans for nationwide expansion.

Sentiment

Score: 7

Explanation: The company shows strong positive momentum in its core telehealth business with significant revenue growth and reduced losses. The strategic divestiture of WorkSimpli to become a pure-play telehealth company is a clear positive for focus. However, persistent material weaknesses in internal controls and ongoing legal proceedings introduce notable risks and uncertainty, tempering overall sentiment.

Positives

• Significant reduction in net loss for both the three and nine months ended September 30, 2025, indicating improved operational efficiency and financial performance.
• Strong telehealth revenue growth of 34% for the nine-month period, driven by increased demand for LifeMD primary care and the GLP-1 Weight Management Program.
• Successful repayment of the $14.0 million Avenue Facility, eliminating a significant portion of convertible long-term debt.
• Strategic divestiture of WorkSimpli allows LifeMD to focus on its core, high-growth telehealth business.
• Expansion into women's health market through the acquisition of OHHMD assets, broadening treatment capabilities.
• Increased acceptance of private health insurance and Medicare for virtual primary care services, enhancing patient access and potential revenue streams.
• Resolution of the IRS tax deficiency case for 2019 in the company's favor, removing a potential liability.
• Cash proceeds of $8.7 million from the At Market Issuance (ATM) Sales Agreement during the quarter, bolstering liquidity.
• The company expects existing cash of $23.8 million to be sufficient to fund operating expenses and capital expenditures for at least the next 12 months.

Negatives

• Working capital deficit slightly increased by approximately $0.5 million to $(15.6) million as of September 30, 2025.
• Gross profit as a percentage of revenues decreased to 88% for the three months and 87% for the nine months ended September 30, 2025, compared to 91% and 90% respectively in the prior year periods, primarily due to increased physician consult fees and product shipping costs.
• WorkSimpli revenue decreased by 2% for the three months ended September 30, 2025, due to a decrease in online sales demand, prior to its divestiture.
• Incurred a $1.2 million loss on debt extinguishment related to the prepayment penalty and fees associated with the Avenue Facility repayment.
• Cash decreased by $11.2 million during the nine months ended September 30, 2025, primarily due to debt repayment.
• Telehealth costs increased to 14% of associated telehealth revenues for the three months and 15% for the nine months ended September 30, 2025, up from 11% and 12% respectively in the prior year periods.

Risks

• Material weaknesses in internal control over financial reporting persist, with an additional weakness identified related to net revenue recording as an agent, which could lead to future misstatements.
• Ongoing putative class action and shareholder derivative complaints alleging violations of the Exchange Act, breach of fiduciary duties, and other claims, which could have a material adverse effect if not favorably resolved.
• Dependence on certain third-party manufacturers and pharmacies for fulfillment services, prescription medications, packaging, and finished goods, with one third-party pharmacy supplying 75% of total fulfillment services as of September 30, 2025.
• Implicit purchase commitments of approximately $727 thousand with inventory vendors, primarily for the RexMD product line.
• Changes in market acceptance of products, competitive products and pricing, and the ability to successfully commercialize products on a large enough scale.
• Inability to respond quickly and effectively to new technological developments, including applications and risks of artificial intelligence (AI).
• Cybersecurity incidents, inability to protect proprietary rights, or infringement upon the rights of others.
• Supply chain constraints or difficulties, general economic and business conditions (inflation, slower growth, recession), and changes in political or regulatory conditions.
• Business interruptions resulting from geo-political actions, including war, terrorism, or disease outbreaks.

Future Outlook

The company expects its existing cash of $23.8 million as of September 30, 2025, to be sufficient to fund planned operating expenses and capital expenditure requirements for at least the next 12 months. The strategic sale of WorkSimpli positions the company as a pure-play telehealth technology company focused on scaling its virtual care and pharmacy operations. LifeMD plans to continue enrollments with private payors and expand Medicare access to medically necessary services nationwide, aiming for broad coverage options across all 50 states. The company also intends to introduce new telehealth product and service offerings that complement its expansive treatment areas.

Management Comments

• We are improving the delivery of the healthcare experience through telehealth with our proprietary technology platform, affiliated and dedicated provider network, broad and expanding treatment capabilities, and the unique ability to nurture patient relationships.
• Our mission is to empower people to live healthier lives by increasing access to high-quality and affordable virtual and in-home healthcare.
• We believe our success has been, and will continue to be, attributable to an amazing patient experience, made possible by attracting and retaining the highest-quality providers in the country, and our vertically integrated care platform.
• As we continue to pursue long-term growth, we plan to continue to introduce new telehealth product and service offerings that complement our already expansive treatment areas.
• The sale of WorkSimpli positions the Company as a pure-play telehealth technology company focused on scaling its virtual care and pharmacy operations.

Industry Context

LifeMD's strategic divestiture of WorkSimpli signals a clear focus on the rapidly expanding direct-to-patient telehealth market. This move aligns with broader industry trends emphasizing specialized virtual care, particularly in high-demand areas like weight management (GLP-1 programs) and women's health. The company's efforts to integrate private and Medicare insurance acceptance are crucial for expanding market reach and competing with larger healthcare providers and digital health platforms. The investment in a wholly-owned affiliated commercial pharmacy and compounding capabilities reflects a vertical integration strategy aimed at improving efficiency and patient experience, a common theme among leading telehealth players seeking to control the end-to-end care journey. The continued growth in telehealth revenue, despite a slight dip in gross margin percentage, suggests strong underlying demand for virtual healthcare services.

Comparison to Industry Standards

• LifeMD's GLP-1 Weight Management Program, with approximately 82,000 patient subscribers, positions it as a significant player in this rapidly growing segment, comparable to offerings from major telehealth competitors like Hims & Hers (HIMS) and Teladoc Health (TDOC) which also offer weight management solutions.
• The expansion into women's health through the OHHMD acquisition allows LifeMD to compete more directly with specialized platforms such as Maven Clinic or Tia, which focus on comprehensive women's health services.
• The establishment of a wholly-owned affiliated commercial pharmacy, designed to fill up to 5,000 daily prescriptions, mirrors strategies seen in larger integrated healthcare systems and some direct-to-consumer pharmacy models, aiming for greater control over fulfillment and cost efficiency.
• The acceptance of private health insurance and Medicare for virtual primary care services is a critical step towards mainstreaming telehealth, aligning with efforts by industry leaders to increase accessibility and reimbursement, moving beyond cash-pay models.
• LifeMD's reported 34% telehealth revenue growth for the nine months ended September 30, 2025, demonstrates strong performance within the telehealth sector, which continues to see robust, albeit normalizing, growth post-pandemic, often outpacing traditional healthcare segments.

Management Changes

Corporate Governance

Legal Proceedings

• A purported shareholder filed a putative class action complaint (Johnston v. LifeMD, Inc., et al.) on August 27, 2025, alleging violations of Section 10(b) and 20(a) of the Exchange Act for false and misleading statements. The case was transferred to the SDNY on October 24, 2025.
• Four putative shareholder derivative complaints (Greenberg, Poulos, Shibata, Ellis v. Schreiber et al.) were filed, alleging violations of Section 14(a), breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of Exchange Act Sections 10(b) and 21D. These are based on similar alleged conduct as the class action.
• The Marden v. LifeMD, Inc. class action complaint, alleging unauthorized disclosure of information, was formally approved for settlement by the District Court of Clark County, Nevada, on September 30, 2025. The company recorded approximately $1.1 million for the estimated settlement liability.
• The IRS income tax deficiency assertion of approximately $1.9 million for the 2019 tax year was resolved in the company's favor by the United States Tax Court on April 1, 2025, with no deficiency due.

Related Party Transactions

• The company utilized CloudBoson Technologies Pvt. Ltd. (owned by WorkSimpli's Chief Software Engineer) for software development services, paying approximately $1.1 million for Q3 2025 and $2.9 million for YTD Sep 2025.
• Will Febbo, a Board member, received 62,500 restricted shares of common stock (fair value $131 thousand) related to a consulting services agreement during YTD Sep 2025.
• Naveen Bhatia, a former Board member, received 56,250 restricted shares of common stock (fair value $168 thousand) and 50,000 restricted shares of common stock (fair value $257 thousand) related to consulting services agreements during YTD Sep 2025.
• Brian Schreiber, Logistics & Fulfillment Advisor and relative of the CEO, received approximately $175 thousand in compensation during YTD Sep 2025. An amendment to his bonus agreement on July 15, 2025, modified performance-based vesting conditions for a 50,000 common share stock option award, resulting in $535 thousand in stock-based compensation expense.

Stakeholder Impact

• Shareholders: Potential positive impact from reduced losses and strategic focus on telehealth, but ongoing legal proceedings and internal control weaknesses pose risks. The WorkSimpli sale provides a cash infusion and a clearer investment thesis.
• Employees: Dr. Doug Lucas's employment agreement and role as VP, Female Health & Clinical Operations, indicates growth in the women's health segment. Changes in compensation for Brian Schreiber reflect adjusted responsibilities.
• Customers/Patients: Expanded access to virtual primary care, weight management, and women's health services, including new insurance and Medicare acceptance, enhances convenience and affordability. The new in-house pharmacy and compounding capabilities aim to improve the care journey.
• Creditors: Repayment of the Avenue Facility significantly reduces debt obligations, improving the company's credit profile.
• Suppliers/Vendors: Continued reliance on third-party pharmacies and manufacturers, with one pharmacy supplying 75% of fulfillment services, indicates concentration risk. Implicit purchase commitments exist with inventory vendors.

Next Steps

• Continue to expand enrollments with private payors to facilitate access to medically necessary services across all 50 states.
• Expand access to qualifying services for Medicare beneficiaries nationwide, aiming for 49 states.
• Introduce new telehealth product and service offerings that complement existing expansive treatment areas.
• Remediate identified material weaknesses in internal control over financial reporting, including formalizing ITGCs, improving IPE review, and modifying revenue reporting controls.
• Defend vigorously against the class action and shareholder derivative complaints.
• Continue to leverage the ATM Sales Agreement for potential future capital raises as needed.

Key Dates

Recommendation

LifeMD's Q3 2025 results show a positive trajectory with significant reductions in net and operating losses, driven by robust telehealth revenue growth. The strategic divestiture of WorkSimpli to focus on the high-growth telehealth sector, particularly in weight management and women's health, is a strong strategic move. However, the company continues to grapple with identified material weaknesses in internal controls over financial reporting, which is a serious concern for investors. Additionally, ongoing class action and shareholder derivative lawsuits introduce legal and reputational risks. While the core business shows promise, these governance and legal challenges warrant a 'hold' recommendation until there is clear evidence of effective remediation of internal control issues and resolution of the legal proceedings, providing greater certainty for future financial stability and operational integrity.

Keywords

telehealth, virtual care, healthcare, WorkSimpli, GLP-1, weight management, SEC filing, 10-Q, financial results, revenue growth, net loss, debt repayment, asset sale, internal controls, legal proceedings, stock compensation, Nasdaq, LFMD